Tue, 20 October 2015
Are There Distinctions Among Currently Available Oral EGFR Inhibitors for EGFR Mutation-Positive NSCLC?
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Direct download: GRACEcast-373_GCVL_LU_Distinctions_Oral_EGFR_Inhibitors_Mutation-Positive_NSCLC.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT